

Date: April 19, 2007

Subject: DRC Recommendations to DCC and DHS

To: DHHS, DCC, Dean's Office

From: Henry F. Simmons, Jr., MD, Ph.D. Chairman DRC

At its 04/19/07 meeting, the Drug Review Committee considered the potential toxicity and therapeutic roles of various drugs used to treat ADHD.

### **Indications under consideration**

ADHDs

### **Agents under consideration**

Amphetamine mixture

Atomoxetine

Dextroamphetamine sulfate

Dexmethylphenidate HCl

Methylphenidate HCL

### **Discussion**

The Committee reached the following conclusions unanimously based upon its perception of the bulk of the best available evidence:

None of the agents differ in comparative safety or occurrence of adverse events to the degree that one or more should be stricken from further consideration.

From a pharmacological standpoint there are no significant differences in effectiveness between the agents on the basis of their release kinetics, specifically IR v. IR, SR v. SR or IR v. SR.

At least one IR methylphenidate preparation and one IR amphetamine preparation should be available.

At least one SR methylphenidate preparation and one SR amphetamine preparation should be available.

Absent some co-morbidities, methylphenidate and amphetamines are more likely to be appropriate initial choices than atomoxetine.

Atomoxetine should be available at least by prior authorization for patients with certain comorbidities, inability to tolerate amphetamines or inability to tolerate methylphenidate.

Alternate dosing forms should be available for patients who cannot swallow anything or who cannot ingest solids.

Henry F. Simmons, Jr.  
April 19, 2007